These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 16632301)

  • 1. The return of natalizumab: weighing benefit against risk.
    Goodin D
    Lancet Neurol; 2006 May; 5(5):375-7. PubMed ID: 16632301
    [No Abstract]   [Full Text] [Related]  

  • 2. Treating multiple sclerosis with natalizumab.
    Iaffaldano P; Lucchese G; Trojano M
    Expert Rev Neurother; 2011 Dec; 11(12):1683-92. PubMed ID: 22091593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
    Bartt RE
    Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The trials and tribulations of Tysabri.
    Lancet Neurol; 2006 May; 5(5):373. PubMed ID: 16632299
    [No Abstract]   [Full Text] [Related]  

  • 5. [Natalizumab in multiple sclerosis: unclear patient benefits].
    Schipper JP
    Ned Tijdschr Geneeskd; 2007 Apr; 151(15):852-5. PubMed ID: 17472115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PML risk and natalizumab: more questions than answers.
    Ransohoff RM
    Lancet Neurol; 2010 Mar; 9(3):231-3. PubMed ID: 20117056
    [No Abstract]   [Full Text] [Related]  

  • 7. Lessons for clinical trials from natalizumab in multiple sclerosis.
    Chaudhuri A
    BMJ; 2006 Feb; 332(7538):416-9. PubMed ID: 16484271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Balancing risk and reward: the question of natalizumab.
    Hauser SL; Johnston SC
    Ann Neurol; 2009 Sep; 66(3):A7-8. PubMed ID: 19810091
    [No Abstract]   [Full Text] [Related]  

  • 9. Multiple sclerosis woes.
    Nat Neurosci; 2005 Jul; 8(7):837. PubMed ID: 16136665
    [No Abstract]   [Full Text] [Related]  

  • 10. How Tysabri survived.
    Huggett B
    Nat Biotechnol; 2009 Nov; 27(11):986. PubMed ID: 19898447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tysabri back on market.
    Sheridan C
    Nat Biotechnol; 2006 Aug; 24(8):874. PubMed ID: 16900111
    [No Abstract]   [Full Text] [Related]  

  • 12. Recommendations for the selection, treatment, and management of patients utilizing natalizumab therapy for multiple sclerosis.
    Foley J
    Am J Manag Care; 2010 Jun; 16(6 Suppl):S178-83. PubMed ID: 20615054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natalizumab (Tysabri) returns.
    Med Lett Drugs Ther; 2006 Sep; 48(1243):76. PubMed ID: 16977289
    [No Abstract]   [Full Text] [Related]  

  • 14. Natalizumab: bound to rebound?
    Schiess N; Calabresi PA
    Neurology; 2009 Feb; 72(5):392-3. PubMed ID: 19188569
    [No Abstract]   [Full Text] [Related]  

  • 15. Natalizumab: bench to bedside and beyond.
    Rudick R; Polman C; Clifford D; Miller D; Steinman L
    JAMA Neurol; 2013 Feb; 70(2):172-82. PubMed ID: 23128399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natalizumab and PML: a risky business?
    Clifford DB
    Gut; 2008 Oct; 57(10):1347-9. PubMed ID: 18791114
    [No Abstract]   [Full Text] [Related]  

  • 17. [Natalizumab in multiple sclerosis].
    Rajda C; Bencsik K; Vécsei L;
    Ideggyogy Sz; 2008 May; 61(5-6):204-8. PubMed ID: 18567397
    [No Abstract]   [Full Text] [Related]  

  • 18. Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS.
    Vennegoor A; Wattjes MP; van Munster ET; Kriekaart RL; van Oosten BW; Barkhof F; Killestein J; Polman CH
    Neurology; 2011 Feb; 76(6):574-6. PubMed ID: 21300973
    [No Abstract]   [Full Text] [Related]  

  • 19. Tysabri's return draws cautious optimism. Pharmacies, infusion centers must register to participate.
    Traynor K
    Am J Health Syst Pharm; 2006 Aug; 63(15):1388, 1392. PubMed ID: 16849700
    [No Abstract]   [Full Text] [Related]  

  • 20. Washout period for immune-modifying drugs before natalizumab therapy.
    Ilanjian H; Shane R
    Am J Health Syst Pharm; 2008 Jan; 65(1):18-9. PubMed ID: 18159033
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.